A parallel phase I/II clinical trial design for combination therapies.
about
Designs of drug-combination phase I trials in oncology: a systematic review of the literatureApproaches to modernize the combination drug development paradigmPhase I/II adaptive design for drug combination oncology trialsContinual reassessment method for partial ordering.A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responsePhase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromesSafety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyUsing short-term response information to facilitate adaptive randomization for survival clinical trialsBayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingAdaptive clinical trial designs in oncology.A comparison of two worlds: How does Bayes hold up to the status quo for the analysis of clinical trials?Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncologyBayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.Dose escalation methods in phase I cancer clinical trials.A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.Dose-toxicity models in oncology.Adaptive clinical trials in oncology.Adaptive designs for dual-agent phase I dose-escalation studies.Phase 1 trial design: is 3 + 3 the best?The future of oncology therapeutics.Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.Modelling PK/QT relationships from Phase I dose-escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations.Bayesian optimal interval design for dose finding in drug-combination trials.BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations.Familywise error control in multi-armed response-adaptive two-stage designs.A latent contingency table approach to dose finding for combinations of two agents.Escalation with overdose control for phase I drug-combination trials.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Some statistical considerations in the clinical development of cancer immunotherapies.Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials.Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs
P2860
Q26996348-9B28AE2F-FEAB-4625-8A5B-56AFC32CE31AQ28072074-0AABFD82-4152-472E-BCF2-731318B4A432Q30409168-CC15CF4C-9F2C-4F99-B051-3C160BBEAFBCQ30423577-66E93522-2328-43B0-9452-2123E94EF346Q32177609-C8604D7E-BADD-493B-B4D0-8BCCAE180B12Q33420276-24118689-12EA-40B9-8B12-EDCDBF5E8D99Q33423777-A8827BBB-0146-439A-82CA-C6EB493141DAQ33876297-C2F10432-EC13-4978-B162-6501F2356F2EQ33880042-FEA00CDE-286F-48C0-B768-E5312455713BQ33904066-C33B3CFD-E8A6-4559-932D-30C7400CC867Q34032803-969FD55B-2ACE-4555-AEB5-B24369E3601DQ34799578-561C8323-3FE9-452B-AE44-4DAD32ADFBB8Q35175343-91ACA488-3BC1-4139-984F-7D289672E6D4Q35206844-E2495D17-5FC5-4CE0-9750-05F7419D711BQ35771013-8F04DB08-D2C2-420E-BE00-18C4DE2BE025Q36036648-7FC6DDF5-1BCB-475E-89FE-5C5802C658C4Q36408968-B5332ED5-8E11-48D9-9A7C-06D0CA17FD3FQ37198192-F34DD535-473B-486D-BF86-20B5710A4DC7Q37552881-26F453AD-9334-445E-8D50-F3B758D5312DQ37829437-03D4BC2C-002E-4A5C-9202-36A0694146AFQ37953783-B3B5A9D8-F8E0-45E1-902D-20ABEF242208Q38090897-244380BE-3E14-4BF9-A4D7-5F6A1F5CCA5AQ38222466-830D100A-66F7-4370-8CC0-AA432C0C5780Q38683944-CF84D11B-34B5-4BBB-8FF8-1D6675B617C8Q38735952-E7DDACF1-2604-45EF-81A5-EF36E86D5E14Q39908884-FCD34B0E-6883-475B-83AA-A7DF14B20F9FQ40732630-4EE424C0-3F3E-4D01-AD02-CC44B96065D9Q41545724-B405FF98-FA32-471D-B724-0BDDD3E0D0A1Q44002670-12ECA6BC-9937-4091-A62C-604BC05E5200Q45308799-9733CE8B-255B-4ACA-A42A-90A461FCD2BEQ45713082-79D0E0B8-981A-4A27-A9F5-17BEFD93CFEAQ45834856-83AC50AF-18D1-4EE8-A8CE-11F6129F4A82Q45952214-2BC4DACD-5A30-4F00-94DA-0D1956CE3D2CQ48369935-4B697A71-2624-4072-A576-4758119546E2Q50542476-D56FFDA9-4952-46A9-9A14-80AD719DA771Q51317650-85844D5B-3CB2-4918-98C0-05C4BD23C76AQ55069897-F98B8ABC-7F3B-4530-94EA-707AB5B1CB49Q55306880-2EAFD814-997F-4D0C-8C3F-5AACCB345F92Q58704560-198EB085-D5D5-4625-9DA9-EF82535A120C
P2860
A parallel phase I/II clinical trial design for combination therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A parallel phase I/II clinical trial design for combination therapies.
@en
A parallel phase I/II clinical trial design for combination therapies.
@nl
type
label
A parallel phase I/II clinical trial design for combination therapies.
@en
A parallel phase I/II clinical trial design for combination therapies.
@nl
prefLabel
A parallel phase I/II clinical trial design for combination therapies.
@en
A parallel phase I/II clinical trial design for combination therapies.
@nl
P2093
P1433
P1476
A parallel phase I/II clinical trial design for combination therapies
@en
P2093
Donald A Berry
Swati Biswas
Xuelin Huang
Yasuhiro Oki
P304
P356
10.1111/J.1541-0420.2006.00685.X
P407
P577
2007-06-01T00:00:00Z